We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...
Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still ...
DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline systemic lupus erythematosus therapies in various stages of clinical ...
The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign ...
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report), with a price ...
Medline today announced that it has expanded its medical surgical prime vendor agreement with Northern California-based ...
CareMessage, the largest patient activation platform in the United States for underserved populations, today announced the launch of their AI Assistant, adding ethical AI tools to their market-leading ...
Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its ...
Hosted on MSN11h
Many dementia cases could be prevented, but far from all: studyBut since the start of last year, two Alzheimer's treatments have been approved in the United States: Biogen's lecanemab and Eli Lilly's donanemab. They work by targeting the build-up of two proteins ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback